IN8bio EBIT Margin 2020-2024 | INAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

IN8bio ebit margin from 2020 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

IN8bio ebit margin from 2020 to 2024. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$160.6B
Vertex Pharmaceuticals (VRTX)	$126.2B
Bristol Myers Squibb (BMY)	$119.7B
Gilead Sciences (GILD)	$117.5B
Regeneron Pharmaceuticals (REGN)	$90.2B
CSL (CSLLY)	$90B
GSK (GSK)	$73.6B
Argenex SE (ARGX)	$35.5B
Alnylam Pharmaceuticals (ALNY)	$34.7B
BioNTech SE (BNTX)	$25.5B
Biogen (BIIB)	$24.5B
Illumina (ILMN)	$23.4B
BeiGene (BGNE)	$18.9B
Moderna (MRNA)	$16.7B
Incyte (INCY)	$15.5B
Genmab (GMAB)	$14.9B
BioMarin Pharmaceutical (BMRN)	$12.6B
Insmed (INSM)	$12.5B
Vaxcyte (PCVX)	$12.4B
Bio-Techne Corp (TECH)	$11.8B
Sarepta Therapeutics (SRPT)	$10.9B
Exelixis (EXEL)	$10.2B
Revolution Medicines (RVMD)	$10B
QIAGEN (QGEN)	$9.9B
Intra-Cellular Therapies (ITCI)	$9.4B
Bio-Rad Laboratories (BIO.B)	$9.4B
Exact Sciences (EXAS)	$9.3B
Roivant Sciences (ROIV)	$8.6B
Repligen (RGEN)	$8.3B
Ascendis Pharma (ASND)	$7.7B